[Inhibitors of the EGFR pathway in non small cell lung cancer: what's new in 2007?].

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Back to search

Article

[Inhibitors of the EGFR pathway in non small cell lung cancer: what's new in 2007?].

Bulletin du cancer - 1 Jan 2007

Grenier Julien, Soria Jean-Charles

Abstract excerpt

Non small cell lung cancer (NSCLC) is a major health public issue because of its frequency and related mortality. Progress with chemotherapy in advanced NSCLC has reached a plateau and more effective and better tolerated therapeutic strategies are needed. Epidermal growth factor receptor (EGFR) is overexpressed in 80% of NSCLC and inhibitors of EGFR tyrosine kinase have now an important place in the management of...

Topics

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Antineoplastic Agents
Carcinoma, Non-Small-Cell Lung
Cetuximab
Clinical Trials, Phase II as Topic
Clinical Trials, Phase III as Topic
ErbB Receptors
Erlotinib Hydrochloride
Gefitinib
Humans
Lung Neoplasms
Mutation
Protein Kinase Inhibitors
Quinazolines

Source

Open in PubMed

Identifiers

PMID: 17237005

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 30 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics